Nasdaq:US$16.23 (+0.19) | HKEX:HK$26.05 (+0.40) | AIM:£2.42 (+0.04)
Search Result
Previous Article   |   Next Article
Scientific Publications | 4 Jun 2021

ASCO 2021: Interim Analysis Results of Surufatinib in US Patients with Neuroendocrine Tumors (NETs)